A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.
Blog|Articles|July 24, 2024
Comprehensive Review of the Nitra Practice Expense Card 2024: Essential for Healthcare Providers?
Advertisement
Healthcare providers face. unique financial challenges, from managing rising costs to navigating lower reimbursement rates. The Nitra™ Visa® Practice Expense Card from Nitra promises to alleviate some of these pressures by offering enhanced control, insights, and significant savings. With the highest cashback in the healthcare sector at 2.2%, this card comes with a host of features designed specifically for medical and healthcare practices.
Additionally, Nitra offers an impressive introductory offer of 5% cash back on medical supply and healthcare-related purchases up to $100K within the first three months. This review explores whether the Nitra Practice Expense Card lives up to its claims
Advertisement
Related to this article
At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.
Gaurav Singh, MD, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.
A 2026 study links Agent Orange exposure to higher odds of acral melanoma in US veterans, highlighting the importance of early detection.
Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.
Phase 2 AMETHYST findings show continued improvements in skin redness and clinician- and patient-reported outcomes with litifilimab.
Advertisement
Advertisement
Trending on Dermatology Times
1
Updated HS Guidelines Emphasize Biologics and Early Intervention
2
Dermatology Times Monthly FDA and Pipeline Review: October 2026
3
Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year
4
Brepocitinib Clears Skin in 69% of Cutaneous Sarcoidosis Patients
5